Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis

Company Overview

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Key Stats

• Today's Range: $0.99 to $1.11
• 50-Day Range: $0.82 to $1.40
• 52-Week Range: $0.80 to $4.16
• Volume: 24,382 shs
• Average Volume: 38,949 shs
• Market Capitalization: $41.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.17
• Consensus Rating: Buy

Barinthus Biotherapeutics Stock Analysis - MarketRank™

Barinthus Biotherapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 654th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Barinthus Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Barinthus Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($1.52) to ($1.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Barinthus Biotherapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Barinthus Biotherapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Barinthus Biotherapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Barinthus Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Barinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Barinthus Biotherapeutics has recently increased by 133.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Barinthus Biotherapeutics does not currently pay a dividend.

Dividend Growth

Barinthus Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.03% of the float of Barinthus Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Barinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Barinthus Biotherapeutics has recently increased by 133.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.01

News Sentiment

Barinthus Biotherapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Barinthus Biotherapeutics this week, compared to 1 article on an average week.

Search Interest

3 people have searched for BRNS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added Barinthus Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.00% of the stock of Barinthus Biotherapeutics is held by insiders.

Percentage Held by Institutions

Only 25.20% of the stock of Barinthus Biotherapeutics is held by institutions.

BRNS Stock Analysis - Frequently Asked Questions

How have BRNS shares performed this year?

Barinthus Biotherapeutics' stock was trading at $1.2080 at the start of the year. Since then, BRNS shares have decreased by 13.9% and is now trading at $1.04.
View the best growth stocks for 2025 here.

How were Barinthus Biotherapeutics' earnings last quarter?

Barinthus Biotherapeutics plc (NASDAQ:BRNS) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.23. The business earned $14.97 million during the quarter.

How do I buy shares of Barinthus Biotherapeutics?

Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Barinthus Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Barinthus Biotherapeutics investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cogent Communications (CCOI), Datadog (DDOG), Intuitive Surgical (ISRG) and nCino (NCNO).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 1/18/2025
• Next Earnings (Estimated): 3/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BRNS
• Previous Symbol: NASDAQ:BRNS
• CUSIP: N/A
• CIK: 1828185
• Web: www.barinthusbio.com
• Phone: 44-1865-818-808
• Fax: N/A
• Employees: 107
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.17
• High Stock Price Target: $9.50
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +396.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-73,350,000.00
• Net Margins: N/A
• Pretax Margin: -392.47%
• Return on Equity: -34.26%
• Return on Assets: -29.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.93
• Quick Ratio: 8.93

Sales & Book Value

• Annual Sales: $14.97 million
• Price / Sales: 2.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.85 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 40,228,000
• Free Float: 37,010,000
• Market Cap: $41.84 million
• Optionable: N/A
• Beta: -0.81